Prime Medicine Inc. outlined updates on its prime editing gene-editing platform, highlighting its approach to making permanent genetic corrections without double-strand breaks or bystander edits. The company said it is prioritizing liver programs in Wilson disease (PM577) and Alpha-1 Antitrypsin Deficiency (PM647), with plans to file regulatory submissions in 2026 and begin Phase 1 clinical trials, and to report initial clinical data in 2027. Prime Medicine also described progress in its ex vivo program for chronic granulomatous disease (PM359), including plans to move toward a biologics license application following regulatory alignment, and noted ongoing work in cystic fibrosis supported by agreements with the Cystic Fibrosis Foundation, as well as an ex vivo T-cell collaboration with Bristol Myers Squibb. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.